voriconazole pharma regulatory solutions 200 milligram pdr for soln for infusion
pharma regulatory solutions ltd - voriconazole - pdr for soln for infusion - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidaemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.
voriconazole actavis 200 mg powder for solution for infusion
actavis group ptc ehf - voriconazole - powder for solution for infusion - 200 milligram(s) - voriconazole
voriconazole accord
accord healthcare s.l.u. - voriconazole - aspergillosis; candidiasis; mycoses - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.voriconazole accord should be administered primarily to patients with progressive, possibly life-threatening infections.
voriconazole hikma (previously voriconazole hospira)
hikma farmaceutica (portugal) s.a. - voriconazole - bacterial infections and mycoses; aspergillosis; candidiasis - antimycotics for systemic use - voriconazole is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections.prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct)recipients.
vfend
pfizer europe ma eeig - voriconazole - candidiasis; mycoses; aspergillosis - antimycotics for systemic use - voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to patients with progressive, possibly life-threatening infections.prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.
vfend tablet
pfizer canada ulc - voriconazole - tablet - 50mg - voriconazole 50mg - azoles
vfend tablet
pfizer canada ulc - voriconazole - tablet - 200mg - voriconazole 200mg - azoles
vfend powder for solution
pfizer canada ulc - voriconazole - powder for solution - 200mg - voriconazole 200mg - azoles
vfend powder for suspension
pfizer canada ulc - voriconazole - powder for suspension - 200mg - voriconazole 200mg - azoles
voriconazole for injection powder for solution
sandoz canada incorporated - voriconazole - powder for solution - 200mg - voriconazole 200mg - azoles